Global Scoring Balloon Catheters Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

What is the Scoring Balloon Catheters Market Size and Growth Rate?

• As per Data Bridge Market Research analysis, the scoring balloon catheters market was valued at USD 480.30 million in 2025 and is projected to reach USD 966.19 million by 2033, growing at a CAGR of 9.13% from 2026 to 2033.
• The market is experiencing steady growth driven by the increasing prevalence of cardiovascular diseases, rising adoption of minimally invasive endovascular procedures, and growing demand for advanced lesion preparation technologies in coronary and peripheral interventions.
• The increasing burden of coronary artery disease (CAD), peripheral artery disease (PAD), and heavily calcified vascular lesions, combined with continuous advancements in interventional cardiology, is encouraging hospitals and cardiac catheterization laboratories to adopt scoring balloon catheters for controlled plaque modification and improved procedural outcomes. Monorail and over-the-wire scoring balloon systems are increasingly being utilized in complex angioplasty procedures, providing enhanced lesion compliance, reduced balloon slippage, and more effective vessel preparation before stent implantation.

Market Size & Forecast

• Global Market Value (2025): USD 480.30 Million
• Expected Market Value (2033): USD 966.19 Million
• Forecast CAGR (2026–2033): 9.13%
• Leading Region in 2025: North America
• Fastest Growing Region: Asia Pacific

What are the Major Takeaways of the Scoring Balloon Catheters Market?

• North America dominated the scoring balloon catheters market with the largest revenue share of 38.10% in 2025, supported by high PCI procedure volumes, advanced interventional cardiology infrastructure, established reimbursement systems, and rapid adoption of lesion preparation technologies
• Asia-Pacific is expected to be the fastest-growing region at a CAGR of 9.91% from 2026 to 2033, fueled by expanding interventional cardiology capacity, increasing cardiovascular disease burden, and rising adoption across China, Japan, and India.
• The non-compliant segment led the market with a 58.3% share in 2025, driven by its superior ability to deliver controlled plaque modification while maintaining balloon diameter even at high inflation pressures
• Semi-compliant are the fastest-growing balloon type, projected to register a CAGR of 8.9%, reflecting the surge in use in less complex lesions and peripheral vascular interventions requiring greater balloon flexibility.
• The nylon segment dominated the material category with a 42.5% revenue share in 2025, led by its excellent flexibility, durability, and ability to withstand high inflation pressures while maintaining consistent balloon performance.
• 3–5 mm accounted for 47.8% of the market share in 2025, preferred by its extensive use in routine coronary angioplasty and peripheral vascular interventions.
• The peripheral segment is the fastest-growing application category, with a CAGR of 9.2%, driven by increasing incidence of peripheral artery disease and expanding utilization of endovascular treatment techniques.

Report Scope and Scoring Balloon Catheters Market Segmentation  

What is the Key Trend in the Scoring Balloon Catheters Market?

• Scoring balloon catheters are increasingly being adopted for the treatment of heavily calcified and complex coronary lesions, offering controlled plaque modification before drug-eluting stent implantation and improving procedural success rates.
• For instance, in March 2024, the U.S. FDA approved Boston Scientific's AGENT Drug-Coated Balloon, the first coronary drug-coated balloon approved in the U.S. for treating coronary in-stent restenosis (ISR), reflecting the growing emphasis on optimized lesion preparation and vessel preparation strategies before or instead of repeat stenting
• scoring technology enables uniform force distribution, minimizes balloon slippage, and improves luminal expansion while reducing vessel trauma during angioplasty procedures.
• Interventional cardiology centers are increasingly incorporating specialty scoring balloons into lesion preparation strategies for calcified stenoses, bifurcation lesions, and in-stent restenosis requiring precise plaque modification.
• For instance, in 2025, Boston Scientific reported results from the ALLIANCE Registry showing AGENT Drug-Coated Balloon achieved a 4.7% one-year target lesion failure (TLF) rate in a real-world population that included a high proportion of calcified lesions, reinforcing the industry's trend toward advanced lesion preparation technologies for complex coronary interventions.
• As healthcare providers continue prioritizing minimally invasive cardiovascular interventions and optimized stent deployment outcomes, adoption of advanced scoring balloon catheters is expected to accelerate across coronary and peripheral vascular procedures.

What are the Key Drivers of the Scoring Balloon Catheters Market?

• The rising prevalence of coronary artery disease, peripheral artery disease, and heavily calcified vascular lesions has significantly increased demand for scoring balloon catheters capable of achieving effective lesion preparation before definitive endovascular treatment.
• For instance, in July 2024, an article published in the European Heart Journal – Cardiovascular Interventions concluded that modified balloons, including scoring balloons, improve lesion preparation for severely calcified coronary lesions prior to stent implantation, supporting their increasing adoption in complex PCI procedures.
• Hospitals and catheterization laboratories are increasingly integrating specialty balloon technologies into percutaneous coronary and peripheral interventions to improve procedural efficiency, stent expansion, and long-term clinical outcomes.
• Manufacturers continue introducing enhanced deliverability features, hydrophilic coatings, and flexible catheter platforms that improve navigation through tortuous anatomy and facilitate treatment of increasingly complex lesions.
• For instance, in September 2023, an article published in the Journal of Clinical Medicine reported that scoring balloon angioplasty significantly improved lesion preparation before drug-coated balloon treatment of coronary lesions, demonstrating superior acute lumen gain compared with conventional balloon angioplasty.
• With cardiovascular disease remaining a leading cause of mortality worldwide, scoring balloon catheters are expected to remain essential tools for complex angioplasty and contemporary lesion preparation strategies

Which Factors are Challenging the Growth of the Next Generation Tobacco Products Market?

• Scoring balloon catheters involve higher procedural costs than conventional angioplasty balloons because of specialized scoring elements, advanced manufacturing technologies, and premium interventional device designs.
• These higher costs restrict adoption across price-sensitive healthcare systems, smaller hospitals, and emerging economies where reimbursement limitations continue influencing purchasing decisions for specialty cardiovascular devices.
• For instance, in February 2024, a study published in JACC: Cardiovascular Interventions analyzing the FDA MAUDE database reported that the most frequent complications associated with cutting/scoring balloon catheters were balloon rupture, pinhole leaks, and shaft break, with balloon rupture occurring more frequently in severely calcified vessels, highlighting the procedural challenges of these specialty devices.
• Complex coronary and peripheral interventions also require experienced interventional cardiologists because improper lesion assessment or device handling may reduce procedural effectiveness and increase intervention complexity.
• Healthcare providers must In addition evaluate procedure costs alongside clinical benefits when selecting specialty lesion preparation devices instead of conventional non-compliant angioplasty balloons for routine interventions.
• For instance, In September 2023, a peer-reviewed study published in the Journal of Clinical Medicine reported that successful scoring balloon angioplasty before drug-coated balloon treatment depended on experienced operators and specialized centers, noting that the results may not be reproducible without an adequate learning curve, which can limit wider adoption.
• The combination of premium device pricing, reimbursement constraints, and operator training requirements continues limiting widespread market penetration despite growing demand for minimally invasive cardiovascular interventions.

How is the Scoring Balloon Catheters Market Segmented?

The scoring balloon catheters market is segmented on the basis of balloon type, material, diameter, application, inflation pressure, and end use.

• By Balloon Type

On the basis of balloon type, the scoring balloon catheters market is segmented into semi-compliant, non-compliant, and others. The non-compliant segment dominated the market with an estimated share of 58.3% in 2025, owing to its superior ability to deliver controlled plaque modification while maintaining balloon diameter even at high inflation pressures. These balloons provide precise lesion preparation, making them the preferred choice for treating calcified and complex coronary lesions before stent implantation. Their high burst pressure and minimal vessel overstretch reduce the risk of vascular injury during angioplasty. Interventional cardiologists increasingly prefer non-compliant scoring balloons for resistant lesions and in-stent restenosis procedures. Continuous product innovations focusing on improved crossability and deliverability are further supporting market growth. Their widespread adoption in coronary interventions continues to reinforce their market leadership.

The semi-compliant segment is projected to register the fastest growth at an estimated CAGR of 8.9% from 2026 to 2033, driven by increasing use in less complex lesions and peripheral vascular interventions requiring greater balloon flexibility. These balloons conform more effectively to varying vessel anatomies, improving navigation through tortuous vasculature. Growing demand for minimally invasive procedures and increasing peripheral artery disease treatment volumes are supporting adoption. Manufacturers are introducing enhanced semi-compliant designs with improved trackability and lesion crossing capabilities. Expanding utilization in emerging healthcare markets is further accelerating growth. Their balance between flexibility and procedural efficiency is expected to drive future demand.

• By Material

On the basis of material, the scoring balloon catheters market is segmented into nylon, PET, polyurethane, and others. The nylon segment dominated the market with an estimated share of 42.5% in 2025 due to its excellent flexibility, durability, and ability to withstand high inflation pressures while maintaining consistent balloon performance. Nylon-based balloons provide superior trackability through complex vascular anatomy, making them suitable for coronary angioplasty procedures. Their high tensile strength supports controlled plaque modification and reduces procedural complications. The material also offers excellent resistance to fatigue during repeated inflation cycles. Manufacturers continue to optimize nylon formulations to improve catheter deliverability and procedural success. Its established clinical acceptance makes nylon the most widely used material in scoring balloon catheter manufacturing.

The PET (polyethylene terephthalate) segment is anticipated to register the fastest growth at an estimated CAGR of 8.6% from 2026 to 2033, supported by increasing demand for high-pressure balloon performance in complex coronary and peripheral interventions. PET offers excellent dimensional stability with minimal balloon compliance, allowing precise lesion dilatation and controlled vessel expansion. The material is increasingly used in advanced scoring balloon designs intended for calcified lesions. Growing preference for specialty balloons in complex PCI procedures is accelerating adoption. Continuous advancements in polymer engineering are improving burst strength and procedural reliability. These performance advantages are expected to strengthen PET demand throughout the forecast period.

• By Diameter

On the basis of diameter, the scoring balloon catheters market is segmented into less than 3 mm, 3–5 mm, and greater than 5 mm. The 3–5 mm segment dominated the market with an estimated share of 47.8% in 2025 owing to its extensive use in routine coronary angioplasty and peripheral vascular interventions. This diameter range provides optimal compatibility with the majority of coronary artery lesion sizes encountered during percutaneous coronary intervention. It offers effective plaque modification while minimizing vessel trauma and procedural complications. Hospitals and cardiac catheterization laboratories routinely utilize these balloon sizes across a wide range of clinical indications. Continuous growth in coronary intervention volumes further supports segment dominance. Their broad clinical applicability continues to maintain strong market demand.

The greater than 5 mm segment is projected to register the fastest growth at an estimated CAGR of 8.8% from 2026 to 2033, driven by rising treatment volumes for peripheral artery disease and large-diameter vascular lesions. These balloons are increasingly utilized in femoral, iliac, and other peripheral vessel interventions requiring greater luminal expansion. Increasing prevalence of peripheral vascular diseases and expanding endovascular treatment options are supporting adoption. Technological improvements in balloon design are enhancing procedural safety in larger vessels. Growing healthcare investment in peripheral intervention programs further contributes to market growth. The segment is expected to benefit from expanding peripheral angioplasty procedures globally.

• By Application

On the basis of application, the scoring balloon catheters market is segmented into coronary and peripheral. The coronary segment dominated the market with a revenue share of 35.2% in 2025, supported by the increasing prevalence of coronary artery disease and the growing number of percutaneous coronary intervention procedures worldwide. Scoring balloon catheters are extensively used for lesion preparation in calcified coronary arteries before stent implantation. They provide controlled plaque modification while reducing balloon slippage and improving stent expansion outcomes. Increasing adoption of minimally invasive cardiovascular procedures continues to strengthen demand. Technological advancements in specialty balloon platforms are improving procedural success rates. Rising investments in interventional cardiology infrastructure further reinforce segment leadership.

The peripheral segment is projected to register the fastest growth at an estimated CAGR of 9.2% from 2026 to 2033, driven by increasing incidence of peripheral artery disease and expanding utilization of endovascular treatment techniques. Scoring balloon catheters are gaining popularity for treating complex femoropopliteal and below-the-knee lesions requiring effective vessel preparation. Growing awareness regarding minimally invasive peripheral interventions is accelerating adoption. Healthcare providers are increasingly utilizing specialty balloons before drug-coated balloon therapy and stent placement. Continuous product innovation focused on peripheral applications is further supporting market expansion. Rising aging populations globally are expected to sustain long-term demand.

• By Inflation Pressure

On the basis of inflation pressure, the scoring balloon catheters market is segmented into low pressure, medium pressure, and high pressure. The high pressure segment dominated the market with an estimated share of 44.6% in 2025 due to its ability to effectively treat resistant and heavily calcified lesions requiring greater radial force during angioplasty. High-pressure scoring balloons facilitate controlled plaque fracture while maintaining precise balloon dimensions throughout the procedure. Their use significantly improves lesion preparation before drug-eluting stent implantation in complex coronary interventions. Increasing prevalence of calcified vascular disease is supporting widespread clinical adoption. Manufacturers continue developing balloons with higher burst pressures and enhanced safety profiles. These advantages continue to strengthen the segment's market position.

The medium pressure segment is projected to register the fastest growth at an estimated CAGR of 8.4% from 2026 to 2033, supported by increasing utilization in routine coronary and peripheral angioplasty procedures involving moderately complex lesions. These balloons provide an effective balance between procedural safety and lesion modification performance. Growing preference for minimally invasive treatment approaches is accelerating demand across hospitals and cardiac centers. Continuous improvements in balloon materials are enhancing inflation consistency and procedural outcomes. Increasing adoption in emerging healthcare systems further contributes to market growth. Their versatility across diverse clinical settings is expected to support long-term expansion.

• By End Use

On the basis of end use, the scoring balloon catheters market is segmented into hospitals, cardiac centers, and others. The hospitals segment accounted for the largest market share of 62.1% in 2025, driven by the concentration of advanced catheterization laboratories, specialized cardiovascular departments, and high procedural volumes. Hospitals perform the majority of complex coronary and peripheral angioplasty procedures requiring specialty lesion preparation devices. Availability of experienced interventional cardiologists and comprehensive emergency care further supports segment dominance. Continuous investment in cardiovascular infrastructure is improving procedural capacity worldwide. Growing patient preference for tertiary care facilities continues to strengthen demand. Hospitals remain the primary end users of advanced scoring balloon catheter technologies.

The cardiac centers segment is projected to register the fastest growth at an estimated CAGR of 9.0% from 2026 to 2033, driven by increasing specialization in minimally invasive cardiovascular procedures and expanding outpatient interventional services. Dedicated cardiac centers provide highly focused expertise in complex coronary interventions using advanced lesion preparation technologies. Rising healthcare expenditure and growing establishment of specialized heart centers are supporting market expansion. Increasing patient demand for efficient, high-quality cardiovascular care is accelerating adoption. Technological advancements in catheterization laboratories continue improving treatment capabilities. Expanding access to specialized cardiac care is expected to sustain strong future growth.

Which Region Holds the Largest Share of the Scoring Balloon Catheters Market?

• North America dominated the scoring balloon catheters market with the largest revenue share of 38.10% in 2025, supported by high PCI procedure volumes, advanced interventional cardiology infrastructure, established reimbursement systems, and rapid adoption of lesion preparation technologies
• The region also benefits from the rising prevalence of coronary artery disease and peripheral artery disease, favorable reimbursement policies, early adoption of advanced lesion preparation technologies, and increasing utilization of minimally invasive cardiovascular procedures across hospitals and cardiac catheterization laboratories. Continuous technological innovation and growing investments in structural heart and complex coronary interventions continue to strengthen North America's leadership position in the global market.

U.S. Scoring Balloon Catheters Market Insight

The U.S. scoring balloon catheters market is witnessing strong growth due to the rising prevalence of coronary artery disease, increasing percutaneous coronary intervention (PCI) volumes, and rapid adoption of advanced lesion preparation technologies. The country's well-established interventional cardiology infrastructure, favorable reimbursement framework, and strong presence of leading medical device manufacturers continue to support market expansion. In addition, growing utilization of minimally invasive cardiovascular procedures and increasing demand for specialty balloons in complex calcified lesions are accelerating product adoption across hospitals and cardiac catheterization laboratories. In March 2024, the U.S. FDA approved Boston Scientific's AGENT Drug-Coated Balloon, the first coronary drug-coated balloon approved in the U.S. for treating coronary in-stent restenosis, highlighting continued innovation in lesion preparation and coronary intervention technologies.

Asia-Pacific Scoring Balloon Catheters Market Insight

The Asia-Pacific scoring balloon catheters market is expected to witness rapid growth, driven by the increasing burden of cardiovascular disease, expanding healthcare infrastructure, and rising adoption of minimally invasive coronary interventions across China, India, Japan, and South Korea. Growing investments in catheterization laboratories, improving access to advanced cardiovascular therapies, and increasing awareness regarding early diagnosis and treatment are supporting regional market expansion. In addition, favorable government healthcare initiatives and the growing presence of multinational medical device manufacturers are accelerating market growth. According to the Asian Pacific Society of Cardiology (APSC), cardiovascular disease remains the leading cause of mortality across the region, significantly increasing demand for advanced coronary intervention devices.

Japan Scoring Balloon Catheters Market Insight

The Japan scoring balloon catheters market is witnessing consistent growth due to the country's aging population, increasing prevalence of calcified coronary lesions, and widespread adoption of advanced interventional cardiology procedures. Japanese hospitals continue to adopt specialty balloon technologies to improve procedural outcomes in complex coronary artery disease. Strong clinical expertise, universal healthcare coverage, and continuous investment in cardiovascular innovation further contribute to market expansion. Japan continues to report one of the world's highest PCI procedure volumes, with more than 250,000 percutaneous coronary interventions performed annually, supporting sustained demand for specialty angioplasty devices.

China Scoring Balloon Catheters Market Insight

The China scoring balloon catheters market is growing rapidly, driven by increasing cardiovascular disease prevalence, expanding hospital infrastructure, and rising adoption of advanced interventional cardiology technologies. Government healthcare reforms, improving access to PCI procedures, and increasing investments in cardiovascular centers are significantly boosting demand for specialty balloon catheters. Growing local manufacturing capabilities and favorable regulatory support are further strengthening market expansion. According to the National Center for Cardiovascular Diseases (China), cardiovascular disease affects over 330 million people in China, making it the country's leading cause of death and driving continuous growth in coronary intervention procedures.

U.K. Scoring Balloon Catheters Market Insight

The U.K. scoring balloon catheters market is experiencing steady growth, supported by increasing adoption of minimally invasive coronary interventions, expanding access to specialist cardiac care, and continuous investments in NHS cardiovascular services. Growing utilization of lesion preparation technologies for calcified coronary artery disease and increasing awareness of evidence-based PCI practices continue to support market expansion. Furthermore, ongoing clinical research and adoption of innovative cardiovascular devices are strengthening the country's interventional cardiology landscape. The British Cardiovascular Intervention Society (BCIS) reports that the U.K. performs over 100,000 PCI procedures annually, supporting sustained demand for advanced coronary intervention devices.

Germany Scoring Balloon Catheters Market Insight

The Germany scoring balloon catheters market is expanding steadily due to the country's advanced cardiovascular healthcare infrastructure, strong medical device industry, and high adoption of innovative interventional cardiology technologies. Hospitals and specialized cardiac centers are increasingly utilizing scoring balloon catheters for treating complex coronary and peripheral lesions requiring precise plaque modification. Continuous investments in catheterization laboratories and physician training programs further support market growth. According to the OECD, Germany performs one of the highest rates of coronary angioplasty (PCI) procedures in Europe, reflecting strong utilization of advanced cardiovascular intervention technologies.

Which are the Top Companies in Scoring Balloon Catheters Market?

The scoring balloon catheters industry is primarily led by well-established companies, including:

• Koninklijke Philips N.V. (Netherlands)
• OrbusNeich Medical Group Holdings Limited (Hong Kong)
• Boston Scientific Corporation (U.S.)
• Abbott (U.S.)
• B. Braun SE (Germany)
• Terumo Corporation (Japan)
• BIOTRONIK SE & Co. KG (Germany)
• Medtronic (Ireland)
• Cardinal Health (U.S.)
• Teleflex Incorporated (U.S.)
• Integer Holdings Corporation (U.S.)
• Asahi Intecc Co., Ltd. (Japan)
• BrosMed Medical Co., Ltd. (China)
• Acrostak AG (Switzerland)
• Balton Sp. z o.o. (Poland)
• iVascular S.L.U. (Spain)
• Lepu Medical Technology (Beijing) Co., Ltd. (China)
• Tokai Medical Products Inc. (Japan)
• Kaneka Corporation (Japan)
• NIPRO CORPORATION (Japan)

What are Latest Developments in Scoring Balloon Catheters Market?

• In August 2024, Philips' AngioSculpt Evo RX PTCA Scoring Balloon Catheter was included in the Australian Register of Therapeutic Goods (ARTG), expanding the commercial availability of the latest-generation scoring balloon catheter in the Australian market. The device features helical nitinol scoring technology designed for controlled plaque modification in complex coronary lesions.
• In March 2024, Boston Scientific received U.S. FDA approval for the AGENT Drug-Coated Balloon Catheter, becoming the first drug-coated coronary balloon approved in the United States for the treatment of coronary in-stent restenosis (ISR). The approval provides interventional cardiologists with a new minimally invasive treatment option and highlights continued innovation in coronary lesion preparation and balloon-based therapies.
• In January 2022, Cardiovascular Systems, Inc. (CSI) and OrbusNeich announced the U.S. commercial launch of the Scoreflex NC Scoring PTCA Catheter following FDA PMA approval. The device is designed with a dual-wire focused-force scoring system for controlled plaque modification in de novo coronary lesions and in-stent restenosis
• In November 2021, Philips introduced the AngioSculpt Evo RX PTCA Scoring Balloon Catheter at TCT 2021. The new-generation scoring balloon features a smaller tip, hydrophilic coating, laser-cut hypotube, and helical nitinol scoring elements to improve deliverability and controlled plaque modification in complex coronary lesions.
• In July 2021, Medtronic announced the European launch of the Prevail Drug Coated Balloon (DCB) Catheter for the treatment of coronary artery disease. The Prevail DCB was designed with enhanced deliverability and a proprietary FreePac coating technology to treat complex coronary lesions while reducing the need for permanent implants, expanding Medtronic's coronary balloon catheter portfolio.

SKU-76592